文献速递胸部肿瘤

阿替利珠单抗联合卡铂加白蛋白结合型紫杉醇化疗对比单纯化疗一线治疗转移性非鳞状非小细胞肺癌(IMpower130):多中心、随机、开放标签、3期试验

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-05-20

IMpower130研究在131个中心入组724例IV期非鳞状非小细胞肺癌患者,随机2:1接受阿替利珠单抗联合卡铂加白蛋白结合型紫杉醇或单纯化疗。在意向治疗野生型人群中,联合组中位总生存期18.6个月对比13.9个月(分层HR 0.79,95%CI 0.64-0.98,p=0.033),中位无进展生存期7.0个月对比5.5个月(分层HR 0.64,95%CI 0.54-0.77,p<0.0001)。安全性谱与已知一致,未发现新安全信号。

要点

  • 在意向治疗野生型人群中,联合组中位总生存期18.6个月对比单纯化疗组13.9个月,分层HR 0.79(95%CI 0.64-0.98,p=0.033)。
  • 联合组中位无进展生存期7.0个月对比单纯化疗组5.5个月,分层HR 0.64(95%CI 0.54-0.77,p<0.0001)。
  • 联合组治疗相关严重不良事件112例(24%)对比单纯化疗组30例(13%),治疗相关死亡8例(2%)对比1例(<1%)。

核心结论

  • IMpower130显示,在无ALK或EGFR突变的IV期非鳞状非小细胞肺癌一线治疗中,阿替利珠单抗联合化疗对比单纯化疗在总生存期和无进展生存期上均有显著且有临床意义的改善,未发现新安全信号。

研究设计与样本

  • 多中心、随机、开放标签、3期研究,在8个国家131个中心进行。
  • 入组724例患者,随机2:1分配至阿替利珠单抗联合化疗组或单纯化疗组。
  • 意向治疗人群723例,其中联合组483例、化疗组240例;意向治疗野生型人群联合组451例、化疗组228例。

主要发现

  • 在意向治疗野生型人群中,联合组中位总生存期18.6个月(95%CI 16.0-21.2)对比化疗组13.9个月(95%CI 12.0-18.7),分层HR 0.79(95%CI 0.64-0.98),p=0.033。
  • 在意向治疗野生型人群中,联合组中位无进展生存期7.0个月(95%CI 6.2-7.3)对比化疗组5.5个月(95%CI 4.4-5.9),分层HR 0.64(95%CI 0.54-0.77),p<0.0001。
  • 联合组对比化疗组最常见的3级或以上治疗相关不良事件:中性粒细胞减少152例(32%)对比65例(28%),贫血138例(29%)对比47例(20%),中性粒细胞计数降低57例(12%)对比19例(8%)。
  • 联合组治疗相关严重不良事件112例(24%)对比化疗组30例(13%);治疗相关(任何治疗)死亡8例(2%)对比1例(<1%)。

关键数值与推荐

  • 阿替利珠单抗1200 mg静脉注射每3周一次,联合卡铂(曲线下面积6 mg/mL每分钟,每3周一次)加白蛋白结合型紫杉醇(100 mg/m2静脉注射每周一次),共4或6个21天周期,随后维持治疗。

临床怎么用

  • 原文结论支持阿替利珠单抗联合铂类化疗作为转移性非小细胞肺癌的一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with chemotherapy as first-line treatment of non-small-cell lung cancer. IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer. METHODS: IMpower130 was a multicentre, randomised, open-label, phase 3 study done in 131 centres across eight countries (the USA, Canada, Belgium, France, Germany, Italy, Spain, and Israel). Eligible patients were aged 18 years or older, and had histologically or cytologically confirmed stage IV non-squamous non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received no previous chemotherapy for stage IV disease. Patients were randomly assigned (2:1; permuted block [block size of six] with an interactive voice or web response system) to receive atezolizumab (1200 mg intravenously every 3 weeks) plus chemotherapy (carboplatin [area under the curve 6 mg/mL per min every 3 weeks] plus nab-paclitaxel [100 mg/m2 intravenously every week]) or chemotherapy alone for four or six 21-day cycles followed by maintenance therapy. Stratification factors were sex, baseline liver metastases, and PD-L1 tumour expression. Co-primary endpoints were investigator-assessed progression-free survival and overall survival in the intention-to-treat wild-type (ie, EGFRwt and ALKwt) population. The safety population included patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02367781. FINDINGS: Between April 16, 2015, and Feb 13, 2017, 724 patients were randomly assigned and 723 were included in the intention-to-treat population (one patient died before randomisation, but was assigned to a treatment group; this patient was excluded from the intention-to-treat population) of the atezolizumab plus chemotherapy group (483 patients in the intention-to-treat population and 451 patients in the intention-to-treat wild-type population) or the chemotherapy group (240 patients in the intention-to-treat population and 228 patients in the intention-to-treat wild-type population). Median follow-up in the intention-to-treat wild-type population was similar between groups (18·5 months [IQR 15·2-23·6] in the atezolizumab plus chemotherapy group and 19·2 months [15·4-23·0] in the chemotherapy group). In the intention-to-treat wild-type population, there were significant improvements in median overall survival (18·6 months [95% CI 16·0-21·2] in the atezolizumab plus chemotherapy group and 13·9 months [12·0-18·7] in the chemotherapy group; stratified hazard ratio [HR] 0·79 [95% CI 0·64-0·98]; p=0·033) and median progression-free survival (7·0 months [95% CI 6·2-7·3] in the atezolizumab plus chemotherapy group and 5·5 months [4·4-5·9] in the chemotherapy group; stratified HR 0·64 [95% CI 0·54-0·77]; p<0·0001]). The most common grade 3 or worse treatment-related adverse events were neutropenia (152 [32%] of 473 in the atezolizumab plus chemotherapy group vs 65 [28%] of 232 in the chemotherapy group), anaemia (138 [29%] vs 47 [20%]), and decreased neutrophil count (57 [12%] vs 19 [8%]). Treatment-related serious adverse events were reported in 112 (24%) of 473 patients in the atezolizumab plus chemotherapy group and 30 (13%) of 232 patients in the chemotherapy group. Treatment-related (any treatment) deaths occurred in eight (2%) of 473 patients in the atezolizumab plus chemotherapy group and one (<1%) of 232 patients in the chemotherapy group. INTERPRETATION: IMpower130 showed a significant and clinically meaningful improvement in overall survival and a significant improvement in progression-free survival with atezolizumab plus chemotherapy versus chemotherapy as first-line treatment of patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations. No new safety signals were identified. This study supports the benefit of atezolizumab, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer. FUNDING: F. Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019. PMID: 31122901. doi:10.1016/S1470-2045(19)30167-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。